Compare Prospect Capital Corporation (PSEC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Zoetis Inc — how do they compare? Prospect Capital Corporation trades at $2.2 (market cap $1.12B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc is far larger — about 27× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (19.27%). Which is the better fit depends on your goals.
| PSEC | ZTS | |
|---|---|---|
Market Cap | $1.12B | $30.29B |
Sector | Financials | Health |
52-Week High | $3.05 | $150.61 |
52-Week Low | $2.11 | $71.91 |
Dividend Yield | 19.27% | 2.89% |
Enterprise Value | — | $37.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $2.19, down 1.79% on the day, with a bearish technical outlook and mixed analyst sentiment. The stock shows a low P/B of 0.39 and has beaten earnings estimates in recent quarters, but revenue volatility and negative net income in 2025 highlight fundamental challenges. Recent news emphasizes its high dividend yield amid portfolio concerns.
The outlook is cautious due to financial deterioration and NAV erosion risks, though the deep discount to book value and consistent dividend payments may appeal to yield-seeking investors. Key risks include declining investment income and persistent underperformance relative to analyst expectations.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
